DNLI - Denali Therapeutics Inc Stock Price, Fair Value and News

$19.00+1.16 (+6.50%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

DNLI Price Action

Last 7 days

-2.1%

Last 30 days

23.7%

Last 90 days

28.5%

Trailing 12 Months

-20.5%

DNLI RSI Chart

DNLI Valuation

Market Cap

2.8B

Price/Earnings (Trailing)

-5.59

Price/Sales (Trailing)

63.7

Price/Free Cashflow

-6.78

DNLI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

DNLI Fundamentals

DNLI Revenue

Revenue (TTM)

33.2M

Rev. Growth (Yr)

-34.15%

Rev. Growth (Qtr)

-8.98%

DNLI Earnings

Earnings (TTM)

-498.7M

Earnings Growth (Yr)

-18.39%

Earnings Growth (Qtr)

-2.24%

DNLI Profitability

Return on Equity

-53.85%

Return on Assets

-47.25%

Free Cashflow Yield

-14.74%

DNLI Investor Care

Shares Dilution (1Y)

1.90%

Diluted EPS (TTM)

-2.91

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	0	0	0	0
2024	311.3M	0	33.2M	0
2023	101.5M	343.1M	340.8M	330.5M
2022	82.9M	112.4M	110.7M	108.5M
2021	263.9M	192.2M	120.4M	48.7M
2020	26.1M	27.7M	23.5M	335.7M
2019	103.5M	77.9M	52.3M	26.7M
2018	0	0	0	129.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative and lysosomal diseases in the United States and internationally. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease; TAK-594/DNL593, which is in Phase I/II clinical trials for the treatment of frontotemporal dementia-granulin; TAK-920/DNL919, which is in Phase I clinical trials for the treatment of Alzheimer's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); SAR443820/DNL788, which is in phase II clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreements with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, Genzyme Corporation, and Centogene. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

CEO	Dr. Ryan J. Watts Ph.D.
WEBSITE	denalitherapeutics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	438

Denali Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Denali Therapeutics Inc? What does DNLI stand for in stocks?

DNLI is the stock ticker symbol of Denali Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Denali Therapeutics Inc (DNLI)?

As of Wed Dec 03 2025, market cap of Denali Therapeutics Inc is 2.79 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DNLI stock?

You can check DNLI's fair value in chart for subscribers.

Is Denali Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether DNLI is over valued or under valued. Whether Denali Therapeutics Inc is cheap or expensive depends on the assumptions which impact Denali Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DNLI.

What is Denali Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, DNLI's PE ratio (Price to Earnings) is -5.59 and Price to Sales (PS) ratio is 63.7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DNLI PE ratio will change depending on the future growth rate expectations of investors.